Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs - Wikidata - awgldk - TriplyDB

Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs

Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs

http://www.wikidata.org/entity/Q33730353

about

Public health service options for affordable and accessible noncommunicable disease and related chronic disease prevention and management Clinical utility of dabigatran in United Arab Emirates. A pharmacovigilance study.Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways A pilot study evaluating the prescribing of ceftriaxone in hospitals in Ghana: findings and implications.Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation.Quality indicators as a tool in improving the introduction of new medicines.Systematic bias in predictions of new drugs' budget impact: analysis of a sample of recent US drug launches.

P2860

Q34584399-5E78D117-E768-430C-8A59-2CE504DA802D Q36356624-E01F8CB3-B4F0-4CCE-A39B-F9F203DA2146 Q37135584-61A33BD7-7E97-4B02-9BC8-8FF1B7E491B6 Q37290101-347E3382-CF5D-4CD8-B264-EA582837E182 Q38665696-567C413B-FFE9-44ED-A79F-60210A6B2101 Q41526451-16025B7B-E6AE-402A-8471-D93CC91D666B Q44695835-F5401FD6-1F1D-4B45-A179-B3B7ACC76B16 Q53241655-55735D14-CB05-494A-89AD-A6507E80FEE3

P2860

Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs

http://www.wikidata.org/entity/Q33730353

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Dabigatran - a continuing exem ...... e the utilization of new drugs

@ast

Dabigatran - a continuing exem ...... e the utilization of new drugs

@en

type

label

Dabigatran - a continuing exem ...... e the utilization of new drugs

@ast

Dabigatran - a continuing exem ...... e the utilization of new drugs

@en

prefLabel

Dabigatran - a continuing exem ...... e the utilization of new drugs

@ast

Dabigatran - a continuing exem ...... e the utilization of new drugs

@en

P1433

Q33730353-0E434DF9-DB5E-4704-B61A-2A73EF988E04

P1476

Q33730353-7FE6412A-0949-4342-A086-72EE39E9068B

P2093

Q33730353-017AB26D-FCC6-4631-8D16-88FB3E3DE55C

Q33730353-09C6E948-B739-4636-84A3-1B821E092C9F

Q33730353-0C21D571-A645-4506-B81C-88903C84B8F4

Q33730353-14E474FC-4984-498D-BE78-8774B957F2B6

Q33730353-166E7DC0-9D78-48B9-B0E9-8EF04D7101E3

Q33730353-17FC92BA-D46F-4FA3-8718-77A7555D5734

Q33730353-1FD708CF-C9DE-401F-A814-98FF5AAA4CB4

Q33730353-2BC5F1C1-44F6-49CF-B823-918786DFEF17

Q33730353-2FC094E7-B1AE-4457-8478-A73F754CA6D7

Q33730353-33799FD9-CC7C-4C4B-BBCC-1018D5E9AC7B

P2860

Q33730353-03DCB7E3-5F61-4D4C-B4D5-2BC5C50842E5

Q33730353-04BE7B99-E991-431A-9321-BEB73A8E3908

Q33730353-0A6C4150-DCAB-49E9-B31E-B0F9801820CD

Q33730353-10B8A3EE-C9B4-49B0-A73C-8B70F8742E25

Q33730353-18CC631B-2164-44C9-B47B-68839D757858

Q33730353-18DE233D-BB51-4288-81D1-0252B84B3E93

Q33730353-318C73E0-B97F-4F45-A2A5-538220796E47

Q33730353-3D43CF28-C068-46A9-9B09-3C26774C0F54

Q33730353-58172859-4FE2-4D29-949C-0B22419DC63D

Q33730353-B202F552-4C36-4D94-92F8-E0F45F0F1E18

P304

Q33730353-6A09C37A-256C-4A14-9B76-5EEC678FA819

P31

Q33730353-86A44F56-F695-4E2A-8E48-323E4C46431C

P356

Q33730353-F8A370E6-743C-4E89-BA1D-286A89258621

P478

Q33730353-4E683451-45AF-47FD-8DFF-0C8416E1537C

P50

Q33730353-2FAF31A3-8A84-45A2-AFFA-B0AD520CF0F2

Q33730353-B58F108D-4962-48AC-90D8-49A8BF2B508A

Q33730353-C82B4928-AC5D-451E-9D82-C99D499C610E

Q33730353-DFBEBE69-9C5E-4D14-879C-06F9E78D7A9C

P577

Q33730353-306657E1-66C4-451A-A0C7-5717E41A3B3D

P5875

Q33730353-D76D7DF8-FD70-4D26-91AC-ED8E58F19B7B

P698

Q33730353-80F9BF91-7830-4D46-AA78-EE9E5486ACFC

P932

Q33730353-3BE35065-126B-46D7-A8A4-B8EEEA848861

P356

FPHAR.2014.00109

P1433

Frontiers in Pharmacology

P1476

Dabigatran - a continuing exem ...... e the utilization of new drugs

@en

P2093

Alexander Finlayson

http://www.w3.org/2001/XMLSchema#string

Anna Brzezinska

http://www.w3.org/2001/XMLSchema#string

Anna Bucsics

http://www.w3.org/2001/XMLSchema#string

Catherine Sermet

http://www.w3.org/2001/XMLSchema#string

Christoph Baumgärtel

http://www.w3.org/2001/XMLSchema#string

Corinne Zara

http://www.w3.org/2001/XMLSchema#string

Dominik Tomek

http://www.w3.org/2001/XMLSchema#string

Eduardo Diogene

http://www.w3.org/2001/XMLSchema#string

Gisbert Selke

http://www.w3.org/2001/XMLSchema#string

Hanne B Pedersen

http://www.w3.org/2001/XMLSchema#string

P2860

Risk scoring and thromboprophylactic treatment of patients with atrial fibrillation with and without access to primary healthcare data: experience from the Stockholm health care system.

Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.

The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).

Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses

Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs.

Prescribing patterns of novel oral anticoagulants following regulatory approval for atrial fibrillation in Ontario, Canada: a population-based descriptive analysis.

Stop the clots, but at what cost? Pharmacoeconomics of dabigatran etexilate for the prevention of stroke in subjects with atrial fibrillation: a systematic literature review.

Assessment of dabigatran utilization and prescribing patterns for atrial fibrillation in a physician group practice setting.

Soft regulations in pharmaceutical policy making: an overview of current approaches and their consequences.

Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research.

P304

109

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FPHAR.2014.00109

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Lars L. Gustafsson

I Gutiérrez-Ibarluzea

P577

2014-06-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263587510

http://www.w3.org/2001/XMLSchema#string

P698

24959145

http://www.w3.org/2001/XMLSchema#string

P932

4050532

http://www.w3.org/2001/XMLSchema#string